-
公开(公告)号：WO2002077216A2
公开(公告)日：2002-10-03
申请号：PCT/EP2002/003393
申请日：2002-03-26
申请人： NOVARTIS AG , NOVARTIS ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. , DE MARTIN, Rainer , HOFER, Erhard , HOFER-WARBINEK, Renate , KALTHOFF, Frank, Stephan , LIPP, Hans-Joachim , MECHTCHERIAKOVA, Diana , SCHMID, Johannes , SOBANOV, Yuri
发明人： DE MARTIN, Rainer , HOFER, Erhard , HOFER-WARBINEK, Renate , KALTHOFF, Frank, Stephan , LIPP, Hans-Joachim , MECHTCHERIAKOVA, Diana , SCHMID, Johannes , SOBANOV, Yuri
IPC分类号： C12N9/12
CPC分类号： C12N9/1205 , A61K39/00 , C07K14/7056 , C12N9/93
摘要： An isolated IKK2-55 gene and polypeptide; DINO gene and polypeptide; LLR-J24-stalk nucleotide and polypeptide,a polynucleotide encoding the transmembrane protein LLR-J24 and the transmembrane protein LLR-J24; a polynucleotide encoding the extracellular domain of LLR-J24 and a polypeptide which is the extracellular domain of LLR-J24; their use in a method of identifying an agonist or antagonist of such polypeptide/protein; and an antagonist or an agonist of such polypeptide/protein and its use as a pharmaceutical.
摘要翻译： 分离的IKK2-55基因和多肽; DINO基因和多肽; LLR-J24-茎核苷酸和多肽，编码跨膜蛋白LLR-J24的多核苷酸和跨膜蛋白LLR-J24; 编码LLR-J24的细胞外结构域的多核苷酸和作为LLR-J24细胞外结构域的多肽; 它们在鉴定这种多肽/蛋白质的激动剂或拮抗剂的方法中的用途; 以及这种多肽/蛋白质的拮抗剂或激动剂及其作为药物的用途。
-
公开(公告)号：WO2008043782A2
公开(公告)日：2008-04-17
申请号：PCT/EP2007/060761
申请日：2007-10-10
申请人： NOVARTIS AG , BAUMRUKER, Thomas , BILLICH, Andreas , MECHTCHERIAKOVA, Diana , WLACHOS, Alexander
CPC分类号： G01N33/564 , G01N2800/102 , G01N2800/104 , G01N2800/285 , G01N2800/52
摘要： The use of CD1 B, or CD1 D, respectively as a target for a disorder selected from Systemic Lupus Erythematosus (SLE), Lupus Anticoagulant (LA) Rheumatoid Arthritis (RA) and Idiopathic Thrombocytopenic Purpura, and the use of CD1 D as a target in a disorder which is Multiple Sclerosis (MS), e g as a biomarker, a method for preparing a diagnostic kit and a method for identifying agents that modulates a disorder which is mediated by elevated levels of CD1 B, or CD1 D, respectively, in case of CD1 B, or CD1 D, respectively selected from Systemic Lupus Erythematosus (SLE), Lupus Anticoagulant (LA) Rheumatoid Arthritis (RA) and Idiopathic Thrombocytopenic Purpura, and in case of CD1 D a disorder which is Multiple Sclerosis (MS)
摘要翻译： 分别使用CD1B或CD1D作为选自系统性红斑狼疮（SLE），狼疮抗凝血剂（LA）类风湿关节炎（RA）和特发性血小板减少性紫癜的疾病的靶标，以及使用CD1D作为靶标 在多发性硬化症（MS）的病症中，例如作为生物标志物，制备诊断试剂盒的方法和鉴定调节由升高的CD1B或CD1D水平介导的病症的药剂的方法 分别选自系统性红斑狼疮（SLE），狼疮抗凝血剂（LA）类风湿关节炎（RA）和特发性血小板减少性紫癜的CD1B或CD1D的情况，以及在CD1D为多发性硬化（MS）的病症的情况下，
-
公开(公告)号：WO2003097028A1
公开(公告)日：2003-11-27
申请号：PCT/EP2003/005125
申请日：2003-05-15
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BAUMRUKER, Thomas , BRINKMANN, Volker , LA MONTAGNE, Kenneth, Richard , LASSOTA, Peter, T. , MECHTCHERIAKOVA, Diana , WOOD, Jeanette, Marjorie
发明人： BAUMRUKER, Thomas , BRINKMANN, Volker , LA MONTAGNE, Kenneth, Richard , LASSOTA, Peter, T. , MECHTCHERIAKOVA, Diana , WOOD, Jeanette, Marjorie
IPC分类号： A61K31/135
CPC分类号： A61K31/137 , A61K31/135 , A61K31/381
摘要： Provided is a method for treating solid tumors, e.g. tumor invasiveness, and particularly inhibiting or controlling deregulated angiogenesis, using a sphingosine-1-phosphate receptor agonist, optionally in combination with a chemotherapeutic agent. The invention also comprises a combination of a sphingosine-1-phosphate receptor agonist with a chemotherapeutic agent.
摘要翻译： 提供了一种治疗实体瘤的方法，例如， 使用鞘氨醇-1-磷酸受体激动剂任选与化学治疗剂组合，特别是抑制或控制去调节的血管发生。 本发明还包括鞘氨醇-1-磷酸受体激动剂与化学治疗剂的组合。
-
公开(公告)号：WO2008043782A3
公开(公告)日：2008-06-26
申请号：PCT/EP2007060761
申请日：2007-10-10
CPC分类号： G01N33/564 , G01N2800/102 , G01N2800/104 , G01N2800/285 , G01N2800/52
摘要： The use of CD1 B, or CD1 D, respectively as a target for a disorder selected from Systemic Lupus Erythematosus (SLE), Lupus Anticoagulant (LA) Rheumatoid Arthritis (RA) and Idiopathic Thrombocytopenic Purpura, and the use of CD1 D as a target in a disorder which is Multiple Sclerosis (MS), e g as a biomarker, a method for preparing a diagnostic kit and a method for identifying agents that modulates a disorder which is mediated by elevated levels of CD1 B, or CD1 D, respectively, in case of CD1 B, or CD1 D, respectively selected from Systemic Lupus Erythematosus (SLE), Lupus Anticoagulant (LA) Rheumatoid Arthritis (RA) and Idiopathic Thrombocytopenic Purpura, and in case of CD1 D a disorder which is Multiple Sclerosis (MS)
摘要翻译： 分别使用CD1B或CD1D作为选自系统性红斑狼疮（SLE），狼疮抗凝血剂（LA）类风湿关节炎（RA）和特发性血小板减少性紫癜的疾病的靶标，以及使用CD1D作为靶标 在多发性硬化（MS）的病症中，例如作为生物标志物，制备诊断试剂盒的方法和鉴定调节由升高的CD1B或CD1D水平介导的病症的药剂的方法 分别选自系统性红斑狼疮（SLE），狼疮抗凝血剂（LA）类风湿关节炎（RA）和特发性血小板减少性紫癜的CD1B或CD1D的情况，以及在CD1D为多发性硬化（MS）的病症的情况下，
-
公开(公告)号：WO2008043725A1
公开(公告)日：2008-04-17
申请号：PCT/EP2007/060637
申请日：2007-10-08
申请人： NOVARTIS AG , BAUMRUKER, Thomas , BILLICH, Andreas , MECHTCHERIAKOVA, Diana , WLACHOS, Alexander
IPC分类号： C12Q1/25
CPC分类号： C12Q1/25 , G01N2333/9015 , G01N2500/00 , G01N2500/04 , G01N2800/102 , G01N2800/104 , G01N2800/285
摘要： The use of SMS2 as a target in autoimmune disorders, e g as a biomarker, e.g. for autoimmune disorders associated wiith inflammation, such as multiple sclerosis, systemic lupus erythematosus, lupus anticoagulant, rheumatoid arthritis, inflammatory bowel disease, idiopathic thrombocytopenic purpura, autoimmune hepatitis (AHI) or fibrosis, diagnostic kits comprising SMS2 and a method for identifying agents that modulates disorders associated with elevated SMS2 levels, or SMS2 activity.
摘要翻译： 使用SMS2作为自身免疫性疾病的靶标，例如生物标志物，例如， 与多发性硬化症，系统性红斑狼疮，狼疮抗凝血剂，类风湿性关节炎，炎性肠病，特发性血小板减少性紫癜，自身免疫性肝炎（AHI）或纤维化相关的自身免疫性疾病，包括SMS2的诊断试剂盒和用于鉴定调节剂的方法 与SMS2水平升高相关的疾病或SMS2活动。
-
公开(公告)号：WO2005030780A1
公开(公告)日：2005-04-07
申请号：PCT/EP2004/010862
申请日：2004-09-28
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BILLICH, Andreas , ETTMAYER, Peter , MECHTCHERIAKOVA, Diana , NUSSBAUMER, Peter , WLACHOS, Alexander
发明人： BILLICH, Andreas , ETTMAYER, Peter , MECHTCHERIAKOVA, Diana , NUSSBAUMER, Peter , WLACHOS, Alexander
IPC分类号： C07F9/113
CPC分类号： C12N9/1205 , C07C219/20 , C07C233/71 , C07C237/08 , C07C237/10 , C07C311/41 , C07C2603/50 , C07D271/12 , C07F9/65324 , C12Q1/42 , C12Q1/485 , G01N2500/02
摘要： The present invention relates to a method (assay) for determining the activity of an enzyme selected from the group consisting of a sphingosine kinase and a phosphatase involved in the sphingolipid pathway by use of a labeled sphingosine.
摘要翻译： 本发明涉及通过使用标记的鞘氨醇来测定选自鞘氨醇激酶和参与神经鞘脂途径的磷酸酶的酶的活性的方法（测定）。
-
公开(公告)号：WO2002077216A3
公开(公告)日：2002-10-03
申请号：PCT/EP2002/003393
申请日：2002-03-26
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , DE MARTIN, Rainer , HOFER, Erhard , HOFER-WARBINEK, Renate , KALTHOFF, Frank, Stephan , LIPP, Hans-Joachim , MECHTCHERIAKOVA, Diana , SCHMID, Johannes , SOBANOV, Yuri
发明人： DE MARTIN, Rainer , HOFER, Erhard , HOFER-WARBINEK, Renate , KALTHOFF, Frank, Stephan , LIPP, Hans-Joachim , MECHTCHERIAKOVA, Diana , SCHMID, Johannes , SOBANOV, Yuri
IPC分类号： C12N9/12
摘要： An isolated IKK2-55 gene and polypeptide; DINO gene and polypeptide; LLR-J24-stalk nucleotide and polypeptide,a polynucleotide encoding the transmembrane protein LLR-J24 and the transmembrane protein LLR-J24; a polynucleotide encoding the extracellular domain of LLR-J24 and a polypeptide which is the extracellular domain of LLR-J24; their use in a method of identifying an agonist or antagonist of such polypeptide/protein; and an antagonist or an agonist of such polypeptide/protein and its use as a pharmaceutical.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.01 秒)
